Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645174 | 0.86 | NAMPT (0.61) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL29728602 | 0.86 | NAMPT (0.61) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL4789781 | 0.85 | ESR2 (0.66) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL17969232 | 0.84 | TMPRSS2 (0.44) | NPC1RAB9ANAMPTPTPN1 | |
| SCHEMBL29728634 | 0.84 | ESR2 (0.56) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL16645224 | 0.84 | ESR2 (0.56) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL16645109 | 0.83 | ESR2 (0.55) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL29728647 | 0.82 | ESR2 (0.53) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL16645145 | 0.82 | ESR2 (0.53) | ESR2NR1H2NPC1RAB9ANAMPT | |
| SCHEMBL5600152 | 0.81 | NR1H2 (0.65) | ESR2NR1H2NPC1RAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| WO-2015054060-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | NAMPT, NAPRT, NNMT | ESR2 4495/4885NR1H2 2307/4885NPC1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.